USD10
BLTE Shares
About Belite BioBelite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
USD10
BLTE Shares
About Belite BioBelite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$6.08B
OPEN PRICE
$159.99
LOW (1Y)
$49.00
HIGH (1Y)
$200.00
LOW (24H)
$153.00
HIGH (24H)
$159.99
VOLUME (24H)
$139.49K
0.59%
Price history
Time | Price | Change |
|---|---|---|
Today | $159.99 | |
1 Day | $154.59 | 0.00% |
1 Week | $159.00 | |
1 Month | $187.06 | |
1 Year | $66.95 |